All Phenotypes Ebf1<tm1.1Rug> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd19^tm1(cre)Cgn/Cd19⁺	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5316373
cn2	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Ighg1^tm1(cre)Cgn/Ighg1⁺	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5316375
cn3	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd79a^tm1(cre)Reth/Cd79a⁺	involves: BALB/c * C57BL/6 * SJL	MGI:5316371
cn4	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺ Tg(BCL2)#Wehi/0	involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi	MGI:5316372
cn5	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Tg(Cr2-cre)3Cgn/0	involves: C57BL/6 * SJL	MGI:5316374
cn6	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺	involves: C57BL/6 * SJL	MGI:5316370

Allelic Composition	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd19^tm1(cre)Cgn/Cd19⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19^tm1(cre)Cgn mutation (11 available); any Cd19 mutation (56 available)
Ebf1^tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

hematopoietic system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

Allelic Composition	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Ighg1^tm1(cre)Cgn/Ighg1⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1^tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)
Ighg1^tm1(cre)Cgn mutation (3 available); any Ighg1 mutation (28 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased germinal center B cell number ( J:182210 )

• 2 to 3 times in immunized mice

hematopoietic system

decreased germinal center B cell number ( J:182210 )

• 2 to 3 times in immunized mice

Allelic Composition	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd79a^tm1(cre)Reth/Cd79a⁺
Genetic Background	involves: BALB/c * C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd79a^tm1(cre)Reth mutation (3 available); any Cd79a mutation (22 available)
Ebf1^tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2

hematopoietic system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2

Allelic Composition	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Polr2a^{tm1(cre/ERT2)Bbd}/Polr2a⁺ Tg(BCL2)#Wehi/0
Genetic Background	involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1^tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)
Polr2a^{tm1(cre/ERT2)Bbd} mutation (3 available); any Polr2a mutation (92 available)
Tg(BCL2)#Wehi mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased immature B cell number ( J:182210 )

• fewer CD25-kappa+ immature B cells in tamoxifen-treated mice

decreased pre-B cell number ( J:182210 )

• fewer CD25+kappa- pre-B cells in tamoxifen-treated mice

hematopoietic system

decreased immature B cell number ( J:182210 )

• fewer CD25-kappa+ immature B cells in tamoxifen-treated mice

decreased pre-B cell number ( J:182210 )

• fewer CD25+kappa- pre-B cells in tamoxifen-treated mice

Allelic Composition	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Tg(Cr2-cre)3Cgn/0
Genetic Background	involves: C57BL/6 * SJL

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1^tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)
Tg(Cr2-cre)3Cgn mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

hematopoietic system

decreased B-1 B cell number ( J:182210 )

• almost complete loss

decreased marginal zone B cell number ( J:182210 )

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:182210 )

N	• tamoxifen-treated mice exhibit normal somatic hypermutation

increased B cell apoptosis ( J:182210 )

• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV

• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells

• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival

decreased B cell proliferation ( J:182210 )

• with cell cycle defects in tamoxifen-treated mice

• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM

• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice

• however, B cell proliferation is rescued by transformation with A-MuLV

decreased immature B cell number ( J:182210 )

• in tamoxifen-treated mice

decreased transitional stage B cell number ( J:182210 )

• in tamoxifen-treated mice

arrested B cell differentiation ( J:182210 )

• of pre-B cells from tamoxifen-treated mice in vitro

decreased germinal center B cell number ( J:182210 )

• in tamoxifen-treated mice, less severe 12 days after immunization

decreased marginal zone B cell number ( J:182210 )

• in tamoxifen-treated mice

decreased pre-B cell number ( J:182210 )

• reduced frequency of B220^intCD43- pre-B cells in tamoxifen-treated mice

increased B cell number ( J:182210 )

• increased number of recirculating B220^hiCD43- B cells in tamoxifen-treated mice

decreased spleen germinal center number ( J:182210 )

• in immunized tamoxifen-treated mice

abnormal germinal center B cell physiology ( J:182210 )

• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice

decreased IgG1 level ( J:182210 )

• by a factor of 5 in tamoxifen treated mice

decreased IgG3 level ( J:182210 )

• by a factor of 3 in tamoxifen treated mice

cellular

increased B cell apoptosis ( J:182210 )

• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV

• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells

• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival

decreased B cell proliferation ( J:182210 )

• with cell cycle defects in tamoxifen-treated mice

• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM

• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice

• however, B cell proliferation is rescued by transformation with A-MuLV

hematopoietic system

increased B cell apoptosis ( J:182210 )

• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV

• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells

• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival

decreased B cell proliferation ( J:182210 )

• with cell cycle defects in tamoxifen-treated mice

• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM

• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice

• however, B cell proliferation is rescued by transformation with A-MuLV

decreased immature B cell number ( J:182210 )

• in tamoxifen-treated mice

decreased transitional stage B cell number ( J:182210 )

• in tamoxifen-treated mice

arrested B cell differentiation ( J:182210 )

• of pre-B cells from tamoxifen-treated mice in vitro

decreased germinal center B cell number ( J:182210 )

• in tamoxifen-treated mice, less severe 12 days after immunization

decreased marginal zone B cell number ( J:182210 )

• in tamoxifen-treated mice

decreased pre-B cell number ( J:182210 )

• reduced frequency of B220^intCD43- pre-B cells in tamoxifen-treated mice

increased B cell number ( J:182210 )

• increased number of recirculating B220^hiCD43- B cells in tamoxifen-treated mice

decreased spleen germinal center number ( J:182210 )

• in immunized tamoxifen-treated mice

abnormal germinal center B cell physiology ( J:182210 )

• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice

decreased IgG1 level ( J:182210 )

• by a factor of 5 in tamoxifen treated mice

decreased IgG3 level ( J:182210 )

• by a factor of 3 in tamoxifen treated mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 05/14/2024 MGI 6.23